Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Resmed Inc (RMD)

Resmed Inc (RMD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

ResMed Earnings Preview: What to Expect

San Diego, California-based ResMed Inc. (RMD) develops, manufactures, distributes, and markets medical devices and cloud-based software applications to diagnose, treat, and manage respiratory disorders in the United States and internationally. Valued at $32.1 billion, the company is expected to release its Q3 2026 earnings soon.

Ahead of the event, analysts expect the company’s EPS to be $2.77 on a diluted basis, up 16.9% from $2.37 in the year-ago quarter. The company has exceeded Wall Street’s EPS estimates in each of its last four quarters.

Fundamentals

See More
  • Market Capitalization, $K 32,117,628
  • Shares Outstanding, K 145,678
  • Annual Sales, $ 5,146 M
  • Annual Income, $ 1,401 M
  • EBIT $ 1,868 M
  • EBITDA $ 2,103 M
  • 60-Month Beta 0.88
  • Price/Sales 6.30
  • Price/Cash Flow 19.86
  • Price/Book 5.13

Options Overview Details

View History
  • Implied Volatility 40.16% (+1.49%)
  • Historical Volatility 21.79%
  • IV Percentile 90%
  • IV Rank 54.54%
  • IV High 56.66% on 04/08/25
  • IV Low 20.36% on 08/13/25
  • Expected Move (DTE 18) 11.84 (5.38%)
  • Put/Call Vol Ratio 0.40
  • Today's Volume 202
  • Volume Avg (30-Day) 232
  • Put/Call OI Ratio 2.83
  • Today's Open Interest 13,173
  • Open Int (30-Day) 12,727
  • Expected Range 208.19 to 231.87

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 19 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate 2.77
  • Number of Estimates 6
  • High Estimate 2.84
  • Low Estimate 2.69
  • Prior Year 2.37
  • Growth Rate Est. (year over year) +16.88%

Price Performance

See More
Period Period Low Period High Performance
1-Month
218.39 +0.75%
on 03/30/26
260.22 -15.44%
on 03/04/26
-36.23 (-14.14%)
since 02/27/26
3-Month
218.39 +0.75%
on 03/30/26
277.67 -20.76%
on 02/10/26
-24.73 (-10.10%)
since 12/26/25
52-Week
199.92 +10.06%
on 04/07/25
293.81 -25.11%
on 08/22/25
+0.09 (+0.04%)
since 03/28/25

Most Recent Stories

More News
ResMed Earnings Preview: What to Expect

ResMed is set to announce its third-quarter earnings soon, and Wall Street expects the company’s EPS to increase by double digits.

XLV : 143.82 (+0.39%)
$SPX : 6,343.72 (-0.39%)
RMD : 220.03 (-0.20%)
Unpacking Q4 Earnings: ResMed (NYSE:RMD) In The Context Of Other Patient Monitoring Stocks

Unpacking Q4 Earnings: ResMed (NYSE:RMD) In The Context Of Other Patient Monitoring Stocks

RMD : 220.03 (-0.20%)
Is ResMed Stock Underperforming the Nasdaq?

ResMed has underperformed the Nasdaq over the past year, but analysts are cautiously optimistic about the stock’s prospects.

$NASX : 20,794.64 (-0.73%)
RMD : 220.03 (-0.20%)
BAX : 15.80 (-1.06%)
ResMed (RMD) Stock Trades Down, Here Is Why

ResMed (RMD) Stock Trades Down, Here Is Why

RMD : 220.03 (-0.20%)
3 Healthcare Stocks to Target This Week

3 Healthcare Stocks to Target This Week

NTRA : 186.84 (+2.29%)
GMED : 83.51 (-0.32%)
RMD : 220.03 (-0.20%)
Resmed’s Global Sleep Survey Reveals Sleep is One of the Top Health Priorities, but Quality Rest Remains Out of Reach

Insights from 30,000 people across 13 countries show global sleep health awareness is growing, yet an action gap remains  53% of people surveyed rank sleep as the most important behavior for a long,...

RMD.AX : 32.150 (+0.37%)
RMD : 220.03 (-0.20%)
Richmond Commences Drilling Program at Aguara East

TORONTO, ON / ACCESS Newswire / February 26, 2026 / Richmond Minerals Inc. (TSX-V:RMD) ("Richmond" or the "Company") is pleased to provide an update for exploration work at the Company's Ridley Lake Gold...

RMD.VN : 0.120 (unch)
RMD : 220.03 (-0.20%)
Resmed Expands U.S. Operations with New Distribution Center in Greenwood, Indiana

SAN DIEGO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing and care delivered in the home, is opening a new distribution...

RMD.AX : 32.150 (+0.37%)
RMD : 220.03 (-0.20%)
ResMed Stock Outlook: Is Wall Street Bullish or Bearish?

As ResMed has outpaced the broader market over the past year, Wall Street analysts maintain a moderately optimistic outlook about the stock’s prospects.

$SPX : 6,343.72 (-0.39%)
MS : 158.37 (-0.01%)
RMD : 220.03 (-0.20%)
IHI : 52.60 (-1.09%)
ResMed (RMD): Buy, Sell, or Hold Post Q4 Earnings?

ResMed (RMD): Buy, Sell, or Hold Post Q4 Earnings?

RMD : 220.03 (-0.20%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength is below 30%. The market is in oversold territory. Watch for a potential trend reversal.

See More Share

Business Summary

ResMed, Inc. holds a major position as designer, manufacturer, as well as a distributor in the worldwide market for generators, masks, and related accessories for the treatment of sleep-disordered breathing (SDB) and other respiratory disorders. SDB includes obstructive sleep apnea (OSA) and other respiratory...

See More

Key Turning Points

3rd Resistance Point 225.50
2nd Resistance Point 223.75
1st Resistance Point 221.89
Last Price 220.03
1st Support Level 218.28
2nd Support Level 216.53
3rd Support Level 214.67

See More

52-Week High 293.81
Fibonacci 61.8% 257.94
Fibonacci 50% 246.86
Fibonacci 38.2% 235.79
Last Price 220.03
52-Week Low 199.92

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.